Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.11 (
CD10
)
9,792
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Different forms of
D-beta-hydroxybutyrate dehydrogenase
were submitted to various proteases in order to get information on enzyme molecular structure and on phospholipid -enzyme interaction. Except for leucinaminopeptidase, all proteases tested inactivated the phospholipid-free enzyme, while no inactivation was observed with the lecithin-enzyme complex. However, non-reactivating phospholipid gave very poor protection against proteases. After
endopeptidase
treatment, a new band of 25,000 Mr appeared instead of the 32,000 Mr band (apodehydrogenase). Surprisingly, the so-called protected form of the enzyme (lecithin-complex) was also proteolysed while still enzymatically active. Carboxypeptidase A inactivated quite thoroughly the enzyme although the 32,000 Mr band appeared unaffected. These results demonstrate that the configuration of the phospholipid-free apodehydrogenase is quite vulnerable to most proteases, in contrast to the configuration of the lecithin-complexed enzyme. The N-terminal end is probably blocked while the C-terminal end looks quite important for enzymatic activity.
...
PMID:Limited proteolysis of D-beta-hydroxybutyrate dehydrogenase: relationships between phospholipid-protein interactions and catalytical activity. 638 1
